Our data showed that 73.1% of patients with MDS accompanied by TP53 abnormalities had complex chromosomal karyotypes, and complex karyotypes were identified as an independent adverse prognostic factor of OS in patients treated with HMA- or venetoclax-based therapies. The gene discussed is TP53; the disease is myelodysplastic syndrome.